---
title: "Genome Plasmid"
ocid: "ocds-r6ebe6-0000801998"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000801998"
markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000801998.md"
json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000801998.json"
source: "Public Contracts Scotland"
current_stage: "Award"
buyer: "UNIVERSITY OF EDINBURGH"
published: "2026-03-31"
---

# Genome Plasmid

Buyer: UNIVERSITY OF EDINBURGH  
Current stage: Award  
OCID: ocds-r6ebe6-0000801998

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000801998)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000801998.json)

## Summary

The University of Edinburgh has successfully concluded a public procurement process, titled "Genome Plasmid," under the industry category of Education. The contract aims to advance a clinical trial for treating a rare genetic disease causing progressive dementia in children. This involves procuring a specially formulated plasmid to meet FDA standards, crucial for manufacturing a lentiviral vector. The procurement process, which involved an open procedure, has reached the award stage with a notable deadline from 1 July 2025, for bid submissions. The goods will be delivered to Los Angeles, USA, directly to the University of California Los Angeles, a partner in this research project.

This tender offers significant opportunities for businesses specialising in genetic and biotechnology research and product development, particularly those with FDA approval experience. Companies with expertise in producing high-quality plasmids for clinical trials can find substantial opportunity for growth. Large-scale operations with a strong track record in FDA approvals and quality management systems like 'GMP' will be well-suited to compete in similar future tenders, given the requirements set by the University of Edinburgh for this project. The procurement's open nature fosters competitive bidding, potentially offering further project scope expansion through additional orders.

## Notice

We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles.

### Lot Information

Lot 1

We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles. This will require the following QC to be performed: - Appearance - Clear, Colorless, No Visible Particulates upon visual inspection - A260:280 - 1.7-2.0 measured by Spectrophotometer - Concentration - 1.0 - 1.1 mg/ml (0.95-1.14mg/ml) measured by Spectrophotometer - Endotoxin - =90% All Supercoiled Forms analysed by Agarose Gel Electrophoresis - Residual RNA - None Detected @ 1.0mg load analysed by Agarose Gel Electrophoresis and Plasmid Safe(tm) Assay - Residual ssDNA - None Detected @ 1.0mg load analysed by Agarose Gel Electrophoresis and Plasmid Safe(tm) Assay - Residual Chromosomal DNA - None Detected @ 1.0mg load analysed by Agarose Gel Electrophoresis and Plasmid Safe(tm) Assay - Residual Linear DNA -

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Public Contracts Scotland |
| Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552953 |
| Notice type | PCS Notice - Website Contract Award Notice |
| Procurement type | Standard |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 31 Mar 2026 |
| Submission deadline | 1 Jul 2025 |
| Future notice date | Not specified |
| Award date | 14 Aug 2025 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £62,000 |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £75,135 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Not specified |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | UNIVERSITY OF EDINBURGH |
| Locality | EDINBURGH |
| Post town | Edinburgh |
| Postcode | EH1 1HT |
| Country | Scotland |
| ITL 1 | TLM Scotland |
| ITL 2 | TLM1 East Central Scotland |
| ITL 3 | TLM13 City of Edinburgh |
| Local authority | City of Edinburgh |
| Electoral ward | City Centre |
| Westminster constituency | Edinburgh East and Musselburgh |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | INDIANA UNIVERSITY |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33140000 - Medical consumables

## Release History

- 31 Mar 2026 at 00:00 - Award - PCS Notice - Website Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552953
- 17 Jun 2025 at 00:00 - Tender - PCS Notice - Website Contract Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUN532782

## Documents

- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=JUN532782
  Genome Plasmid - We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles.
- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552953
  Genome Plasmid - We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh's partner in the project, University of California Los Angeles.

## Notice URLs

- http://
- http://www.ed.ac.uk
- https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000801998
- https://www.publictendersscotland.publiccontractsscotland.gov.uk/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000801998. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000801998.json.